This is very early pre-clinical data - any accelerated approval is years away, after a long run of expensive and risky clinical trials.
In the context of promotional, unpublished data, based on a vague and undisclosed experimental program, I don't know what 'crossing the blood brain barrier' even means.
Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size, page-53
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $130 | 32.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 29118308 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 8604045 | 13 |
View Market Depth
| Last trade - 13.17pm 19/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |